56.68

2.43% -1.41

After Hours: 56.52 -0.16 -0.28%

Crispr Therapeutics Ag (CRSP)

Overview News Price History Option Chain Financials Why CRSP Down? Discussions Forecast

Crispr Therapeutics Ag stock is traded at $56.68, with a volume of 1.40M. It is down -2.43% in the last 24 hours and up +8.60% over the past month. Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Previous Close:

$58.09

Open:

$57.95

24h Volume:

1.40M

Relative Volume:

0.56

Market Cap:

$5.40B

Revenue:

$170.10M

Net Income/Loss:

$-239.59M

P/E Ratio:

-20.24

EPS:

-2.8

Net Cash Flow:

$-191.20M

1W Performance:

-0.35%

1M Performance:

+8.60%

6M Performance:

+37.31%

1Y Performance:

+24.85%

1-Day Range:

$55.52

$58.50

1-Week Range:

$54.41

$59.24

52-Week Range:

$30.04

$78.48

Crispr Therapeutics Ag Stock (CRSP) Company Profile

Name

Crispr Therapeutics Ag

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

(617) 315-4600

Address

BAARERSTRASSE 14, ZUG

Employee

393

Twitter

@crisprtx

Next Earnings Date

2025-10-31

Latest SEC Filings

CRSP's Discussions on Twitter

Compare CRSP with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRSP Crispr Therapeutics Ag	56.68	5.54B	170.10M	-239.59M	-191.20M	-2.80
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-18-25	Initiated	JP Morgan	Overweight
Feb-14-25	Upgrade	Evercore ISI	In-line → Outperform
Feb-12-25	Upgrade	TD Cowen	Sell → Hold
Feb-03-25	Initiated	H.C. Wainwright	Buy
Aug-06-24	Reiterated	Needham	Buy
Aug-02-24	Initiated	Rodman & Renshaw	Buy
Jun-28-24	Resumed	Guggenheim	Neutral
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-11-23	Downgrade	TD Cowen	Market Perform → Underperform
Oct-17-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-27-23	Initiated	Mizuho	Buy
Aug-17-23	Upgrade	Citigroup	Neutral → Buy
May-30-23	Initiated	William Blair	Outperform
Apr-13-23	Initiated	Cantor Fitzgerald	Overweight
Mar-21-23	Initiated	Bernstein	Mkt Perform
Mar-17-23	Initiated	Bryan Garnier	Buy
Mar-07-23	Initiated	Robert W. Baird	Neutral
Oct-11-22	Initiated	Morgan Stanley	Underweight
Aug-09-22	Downgrade	Barclays	Overweight → Equal Weight
Jun-23-22	Downgrade	Evercore ISI	Outperform → In-line
Jun-17-22	Initiated	BMO Capital Markets	Outperform
Apr-28-22	Initiated	Credit Suisse	Neutral
Dec-07-21	Initiated	Cowen	Market Perform
Oct-19-21	Initiated	SVB Leerink	Outperform
Jun-14-21	Upgrade	Citigroup	Sell → Neutral
Apr-21-21	Upgrade	Jefferies	Hold → Buy
Mar-04-21	Initiated	JMP Securities	Mkt Outperform
Dec-10-20	Reiterated	Chardan Capital Markets	Buy
Dec-10-20	Downgrade	Jefferies	Buy → Hold
Dec-10-20	Reiterated	Needham	Buy
Dec-07-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Oct-23-20	Initiated	RBC Capital Mkts	Sector Perform
Oct-05-20	Initiated	BofA Securities	Buy
Jul-28-20	Reiterated	Needham	Buy
Jul-14-20	Initiated	SunTrust	Buy
Jun-15-20	Reiterated	Canaccord Genuity	Buy
Mar-05-20	Initiated	Stifel	Hold
Feb-03-20	Downgrade	Evercore ISI	Outperform → In-line
Nov-19-19	Upgrade	William Blair	Mkt Perform → Outperform
Nov-12-19	Upgrade	Oppenheimer	Perform → Outperform
Aug-01-19	Initiated	Jefferies	Buy
Jul-26-19	Initiated	Canaccord Genuity	Buy
Jun-10-19	Initiated	ROTH Capital	Buy
Apr-12-19	Initiated	Evercore ISI	Outperform
Mar-14-19	Initiated	William Blair	Mkt Perform
Jan-28-19	Downgrade	Goldman	Buy → Neutral
Jan-22-19	Downgrade	Citigroup	Neutral → Sell

View All

Crispr Therapeutics Ag Stock (CRSP) Latest News

Dec 13, 2025

CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat

Dec 13, 2025

Dec 12, 2025

2 Healthcare Stocks to Buy Ahead of the New Year - Finviz

Dec 12, 2025

CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors - ts2.tech

Dec 12, 2025

Dec 11, 2025

New York State Common Retirement Fund Increases Position in CRISPR Therapeutics AG $CRSP - MarketBeat

Dec 11, 2025

Dec 10, 2025

Why Is CRISPR Therapeutics (CRSP) Up 3.3% Since Last Earnings Report? - sharewise.com

Dec 10, 2025

Buy Rating for Crispr Therapeutics AG: Pediatric Market Potential and Long-term Growth Opportunities - TipRanks

Dec 10, 2025

Dec 09, 2025

Is CRISPR Therapeutics (CRSP) Turning Early CTX310 Signals Into a Durable Genetic Medicine Platform? - Sahm

Dec 09, 2025

Guggenheim Capital LLC Sells 37,778 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat

Dec 09, 2025

Norges Bank Invests $19.77 Million in CRISPR Therapeutics AG $CRSP - MarketBeat

Dec 09, 2025

Dec 08, 2025

CRISPR Therapeutics AG Stock Analysis and ForecastMarket Sentiment Indicators & High Profit Market Ideas - earlytimes.in

Dec 08, 2025